Skip to content

Advertisement

  • Correction
  • Open Access

Correction to: Targeted therapy against Bcl-2-related proteins in breast cancer cells

  • 1,
  • 2Email author,
  • 1,
  • 1 and
  • 1
Breast Cancer Research201921:26

https://doi.org/10.1186/s13058-019-1105-4

  • Received: 22 January 2019
  • Accepted: 22 January 2019
  • Published:

The original article was published in Breast Cancer Research 2005 7:R940

Correction to: Breast Cancer Res

https://doi.org/10.1186/bcr1323

After the publication of this work [1] errors were noticed in Figs. 1a, 6a, and 8a—in which the β-actin bands were mistakenly presented. The corrected Figs. 1, 6, and 8 are presented below. The correction does not affect our conclusions. Nevertheless, we apologize for this error.
Fig. 1
Fig. 1

Expression levels of Bcl-2 and Bcl-xL proteins in MDA-MB-231, MDA MD-453, BT-474, and ZR-75-1 cells. a Western blot analysis of Bcl-2 and Bcl-xL expression. b Quantification of Bcl-2 and Bcl-xL expression by densitometric analysis. The relative expression of Bcl-2 and BclxL in MDA-MB-453 cells was compared with the expression in MDAMB-231, BT-474, and ZR-75-1 cells. Results are from two representative, independent experiments

Fig. 6
Fig. 6

Effects of treatment with antisense Bcl-2 and mitomycin C, doxorubicin, paclitaxel, or docetaxel on BT-474 cells. a Expression levels of Bcl-2 and Bcl-xL protein in BT-474 cells transplanted into athymic mice after treatment with antisense (AS) Bcl-2 oligodeoxynucleotides (ODNs) were measured by Western blot analysis at the indicated time points. b Enhancement of the antitumor effects of anticancer drugs by AS Bcl-2 ODNs in BT-474 tumor xenografts. Each point represents the mean tumor volume of the eight mice in each group. Error bars indicate SD. *, P < 0.05, analysis of variance with Fisher's least significant difference test. The data presented are from two independent experiments. MMC, mitomycin C; DOX, doxoru- bicin;TXL, paclitaxel; TXT, docetaxel

Fig. 8
Fig. 8

Effects of treatment with antisense Bcl-xL and mitomycin C, doxorubicin, paclitaxel, or docetaxel on MDA-MB-231 cells. a Expression levels of Bcl-xL and Bcl-2 protein in MDA-MB-231 cells transplanted into athymic mice after treatment with antisense (AS) Bcl-xL oligodeoxynucleotides (ODNs) were measured by Western blot analysis at the indicated time points. b Enhancement of the antitumor effects of anticancer drugs by AS Bcl-xL ODNs in MDA-MB-231 tumor xenografts. Each point represents the mean tumor volume of the four mice in each group. Error bars indicate SD. *, P< 0.05, analysis of variance with Fisher's least significant difference test. The data presented are from two independent experiments. MMC, mitomycin C; DOX, doxorubicin; TXL, paclitaxel; TXT, docetaxel

Notes

Declarations

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
(2)
International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

Reference

  1. Emi, et al. Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res. 2005;7:R940. https://doi.org/10.1186/bcr1323.View ArticleGoogle Scholar

Copyright

© The Author(s). 2019

Advertisement